EA201270560A1 - Спиропиперидиновые соединения и их фармацевтическое применение для лечения диабета - Google Patents

Спиропиперидиновые соединения и их фармацевтическое применение для лечения диабета

Info

Publication number
EA201270560A1
EA201270560A1 EA201270560A EA201270560A EA201270560A1 EA 201270560 A1 EA201270560 A1 EA 201270560A1 EA 201270560 A EA201270560 A EA 201270560A EA 201270560 A EA201270560 A EA 201270560A EA 201270560 A1 EA201270560 A1 EA 201270560A1
Authority
EA
Eurasian Patent Office
Prior art keywords
diabetes
spyropyperidine
compounds
treatment
pharmaceutical applications
Prior art date
Application number
EA201270560A
Other languages
English (en)
Russian (ru)
Inventor
Чафик Амдоучи
Джаяна Панкадж Лайнсвала
Пранаб Маити
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43719548&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201270560(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201270560A1 publication Critical patent/EA201270560A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA201270560A 2009-10-15 2010-10-11 Спиропиперидиновые соединения и их фармацевтическое применение для лечения диабета EA201270560A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25183909P 2009-10-15 2009-10-15
US30333410P 2010-02-11 2010-02-11
PCT/US2010/052126 WO2011046851A1 (en) 2009-10-15 2010-10-11 Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes

Publications (1)

Publication Number Publication Date
EA201270560A1 true EA201270560A1 (ru) 2012-09-28

Family

ID=43719548

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201270560A EA201270560A1 (ru) 2009-10-15 2010-10-11 Спиропиперидиновые соединения и их фармацевтическое применение для лечения диабета

Country Status (25)

Country Link
US (1) US8383642B2 (cg-RX-API-DMAC7.html)
EP (1) EP2488500A1 (cg-RX-API-DMAC7.html)
JP (1) JP2013508279A (cg-RX-API-DMAC7.html)
KR (1) KR20120051777A (cg-RX-API-DMAC7.html)
CN (1) CN102574807A (cg-RX-API-DMAC7.html)
AR (1) AR078522A1 (cg-RX-API-DMAC7.html)
AU (1) AU2010307094A1 (cg-RX-API-DMAC7.html)
BR (1) BR112012008889A2 (cg-RX-API-DMAC7.html)
CA (1) CA2777775A1 (cg-RX-API-DMAC7.html)
CL (1) CL2012000921A1 (cg-RX-API-DMAC7.html)
CO (1) CO6531458A2 (cg-RX-API-DMAC7.html)
CR (1) CR20120177A (cg-RX-API-DMAC7.html)
DO (1) DOP2012000105A (cg-RX-API-DMAC7.html)
EA (1) EA201270560A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP12011799A (cg-RX-API-DMAC7.html)
IL (1) IL218344A0 (cg-RX-API-DMAC7.html)
MA (1) MA33662B1 (cg-RX-API-DMAC7.html)
MX (1) MX2012004420A (cg-RX-API-DMAC7.html)
NZ (1) NZ598972A (cg-RX-API-DMAC7.html)
PE (1) PE20121437A1 (cg-RX-API-DMAC7.html)
PH (1) PH12012500705A1 (cg-RX-API-DMAC7.html)
TN (1) TN2012000152A1 (cg-RX-API-DMAC7.html)
TW (1) TW201124415A (cg-RX-API-DMAC7.html)
WO (1) WO2011046851A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201202560B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2628077C2 (ru) * 2013-04-18 2017-08-14 Хендэ Фарм Ко., Лтд Новое производное 3-(4-(бензилокси)фенил)гекс-4-иновой кислоты, способ его получения и фармацевтическая композиция для профилактики и лечения метаболического заболевания, включающая его в качестве эффективного ингредиента

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120834A1 (es) 2009-03-23 2012-07-25 Glenmark Pharmaceuticals Sa Derivados de furopirimidindiona como moduladores de trpa1
ES2456515T3 (es) 2009-03-23 2014-04-22 Glenmark Pharmaceuticals S.A. Derivados de pirimidindiona fusionados como moduladores de TRPA1
AR078948A1 (es) 2009-11-30 2011-12-14 Lilly Co Eli Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes
PH12012501456A1 (en) 2009-12-25 2012-10-29 Mochida Pharm Co Ltd Novel 3-hydroxy -5- arylisothiazole derivative
AU2011313191A1 (en) 2010-10-08 2013-05-02 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
EP2683251B1 (en) 2011-03-11 2021-08-25 Intercontinental Great Brands LLC Method of forming multilayer confectionery
AR085990A1 (es) 2011-04-27 2013-11-13 Mochida Pharm Co Ltd Derivados de 1-oxido de 3-hidroxiisotiazol utiles en el tratamiento de la diabetes y composiciones farmaceuticas que los contienen
JPWO2012147516A1 (ja) 2011-04-28 2014-07-28 持田製薬株式会社 環状アミド誘導体
AR087451A1 (es) 2011-08-17 2014-03-26 Lilly Co Eli Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes
WO2013139341A1 (en) * 2012-03-20 2013-09-26 Syddansk Universitet Gpr120 receptor modulators
WO2013185766A1 (en) * 2012-06-15 2013-12-19 Syddansk Universitet Gpr120 receptor modulators
UY35143A (es) 2012-11-16 2014-05-30 Bristol Myers Squibb Co Derivados de dihidropirazol como moduladores del receptor acoplado a la proteína gpr40 g
CN105722841A (zh) * 2013-11-14 2016-06-29 卡迪拉保健有限公司 新型杂环化合物
US20150351889A1 (en) 2014-06-05 2015-12-10 Vivex Biomedical Inc. Dynamic Biometric Mesh
EP3207928B1 (en) * 2014-10-17 2021-03-10 Hyundai Pharm Co., Ltd. Composite preparation, containing novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative and another active ingredient, for preventing or treating metabolic diseases
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
CN109666027A (zh) * 2017-10-17 2019-04-23 中国科学院上海药物研究所 一类酰胺结构的gpr40激动剂化合物及其用途
DK3737470T5 (da) 2018-01-08 2024-05-27 Celon Pharma Sa 3-phenyl-4-hexynsyrederivater som gpr40-agonister
WO2019160882A1 (en) 2018-02-13 2019-08-22 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
KR102591947B1 (ko) 2018-04-19 2023-10-25 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
PE20210642A1 (es) 2018-07-13 2021-03-23 Gilead Sciences Inc Inhibidores de pd-1/pd-l1
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ,インク. Gpr119アゴニスト
MX2022010548A (es) 2020-02-28 2022-09-23 Kallyope Inc Agonistas de gpr40.
MX2022014505A (es) 2020-05-19 2022-12-13 Kallyope Inc Activadores de la ampk.
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2033644A1 (en) 2001-04-18 2009-03-11 Euro-Celtique S.A. Spiroindene and spiroindane compounds
CA2520114A1 (en) * 2003-04-04 2004-10-21 Merck & Co., Inc. Acylated spiropiperidine derivatives as melanocortin-4 receptor agonists
US7504506B2 (en) 2003-11-04 2009-03-17 Elixir Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
WO2005051890A1 (en) 2003-11-19 2005-06-09 Smithkline Beecham Corporation Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40
EP1737809B1 (en) 2004-02-27 2013-09-18 Amgen, Inc Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
JP4859665B2 (ja) 2004-03-30 2012-01-25 武田薬品工業株式会社 アルコキシフェニルプロパン酸誘導体
US7582803B2 (en) 2005-09-14 2009-09-01 Amgen Inc. Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders
EP2061760A1 (en) 2006-09-07 2009-05-27 Amgen, Inc Benzo-fused compounds for use in treating metabolic disorders
TWI421070B (zh) 2007-10-26 2014-01-01 Japan Tobacco Inc 螺化合物及其醫藥用途
EP2224803B1 (en) 2007-11-21 2014-04-02 Janssen Pharmaceutica N.V. Spiropiperidines for use as tryptase inhibitors
AR078948A1 (es) 2009-11-30 2011-12-14 Lilly Co Eli Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2628077C2 (ru) * 2013-04-18 2017-08-14 Хендэ Фарм Ко., Лтд Новое производное 3-(4-(бензилокси)фенил)гекс-4-иновой кислоты, способ его получения и фармацевтическая композиция для профилактики и лечения метаболического заболевания, включающая его в качестве эффективного ингредиента

Also Published As

Publication number Publication date
CR20120177A (es) 2012-06-06
AR078522A1 (es) 2011-11-16
ECSP12011799A (es) 2012-07-31
PE20121437A1 (es) 2012-10-26
CL2012000921A1 (es) 2012-09-14
CA2777775A1 (en) 2011-04-21
NZ598972A (en) 2013-06-28
DOP2012000105A (es) 2013-01-31
JP2013508279A (ja) 2013-03-07
EP2488500A1 (en) 2012-08-22
CO6531458A2 (es) 2012-09-28
PH12012500705A1 (en) 2012-10-29
MX2012004420A (es) 2012-05-08
MA33662B1 (fr) 2012-10-01
US20110092531A1 (en) 2011-04-21
WO2011046851A1 (en) 2011-04-21
TW201124415A (en) 2011-07-16
AU2010307094A1 (en) 2012-04-19
KR20120051777A (ko) 2012-05-22
IL218344A0 (en) 2012-04-30
CN102574807A (zh) 2012-07-11
BR112012008889A2 (pt) 2019-09-24
US8383642B2 (en) 2013-02-26
TN2012000152A1 (en) 2013-12-12
ZA201202560B (en) 2013-09-25

Similar Documents

Publication Publication Date Title
EA201290416A1 (ru) Новые спиропиперидиновые соединения
EA201290089A1 (ru) Химические соединения
EA201391568A1 (ru) Новые производные имидазола, подходящие для лечения артрита
UA110983C2 (uk) Похідна 1,2,3,4-тетрагідрохіноліну, придатна для лікування діабету
EA201201677A1 (ru) Производные гетероарилимидазолона в качестве ингибиторов jak
EA201290632A1 (ru) Производные бетулина
EA201100750A1 (ru) Замещенные диоксопиперидинилфталимидные производные
EA201170772A1 (ru) Органические соединения
CO6531458A2 (es) Nuevos compuestos de espiropiperidina
EA201200938A1 (ru) Производные имидазопиридина в качестве ингибиторов jak
EA201301209A1 (ru) Производные пирролотриазинона в качестве ингибиторов p13k
EA201891103A1 (ru) Композиции для лечения спинальной мышечной атрофии
EA201692506A2 (ru) Ингибиторы репликации вирусов гриппа
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
EA201300250A1 (ru) Оксадиазольные ингибиторы продуцирования лейкотриена
EA201001847A1 (ru) Соединения и композиции, применяемые для лечения малярии
EA201290121A1 (ru) Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов
EA201101583A1 (ru) Ингибиторы pi3 киназы или mtor
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
EA201170617A1 (ru) Пиразолиламинопиридины в качестве ингибиторов fak
EA201200472A1 (ru) Сульфонамиды в качестве ингибиторов белков семейства bcl-2, предназначенные для лечения рака
EA201391525A1 (ru) Гликозидные производные и их применение для лечения диабета
EA201490650A1 (ru) Фармацевтические композиции
EA201390626A1 (ru) Производные гидроксамовой кислоты и применение указанных производных в лечении бактериальных инфекций